A logo page that reads Hotcopper Podcast on a stylised market background.
Source: The Market Online
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Welcome to this week’s HotCopper market-watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I will take you through all the week’s biggest news headlines and what they mean for Aussie investors.

In Episode 4, it’s all about Trump: The U.S. President has made good on his tariff threats – and, at the same time, waded deeper into the Russia-Ukraine debates.

Also on the docket, Tesla’s sales struggles Down Under, the possible looming end of the Mesoblast (ASX:MSB) juggernaut run, OPEC Plus stopping its oil price prop up, KALiNA Power (ASX:KPO) and its cash problems, and lamb.

We also take a peek under the hood to see what HotCopper users have watched this week.

For the full podcast episode, you can listen above – right here in the browser.

Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
The Market Online Video

ASX Market Close: Elixir pops as Neil Young steps down; US futures green & more

The local bourse traded green on Monday with IT in the lead up 2.6% led by…
Gold spot market concept

Macquarie puts the screws on Bellevue as $156.5M raise announced; job cuts to come

First and foremost, to call this a Bellevue Gold (ASX:BGL) led raise would perhaps be a distortion of the
The Market Online Video

Why most investors fail and how the top 20% succeed

This week on Money and Investing, Mitch Olarenshaw and I talk about why 80% of investors fail and what sets the top 20%
The Market Online Video

Neurizon Therapeutics announces strong safety results in latest study

Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics (ASX:NUZ)